Take a trial of UK to unlock this pageFind out more


CRX 106p 0.0  0.0%
26/05/16 3.00k

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2010 2011 2012 2013 2014 2015 2016E 2017E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p

FINANCIAL BRIEF: For the fiscal year ended 31 December 2015, Cyprotex plc revenues increased 35% to L15.6M. Net loss increased 56% to L6.5M. Revenues reflect United Kingdom segment increase from L1.9M to L3.9M, Rest of Europe segment increase of 34% to L4.4M. Higher net loss reflects Administrative costs - Other increase of 7% to L10.1M (expense), Movement in Loan Note derivative value decrease from L242K (income) to L0K. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Dec '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2016
31st Dec 2017

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Cyprotex
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
N+1 Singer Jens Lindqvist Sheena Berry ,

Profile Summary

Cyprotex PLC (Cyprotex) is a United Kingdom-based holding company. The Company is engaged in providing in vitro and in silico ADMET and PK (Absorption, Distribution, Metabolism, Excretion, Toxicity and Pharmacokinetics) information to various industries including the pharmaceutical, biotechnology, cosmetic, personal care, agrochemical, chemical industries and academia. The Company’s trading subsidiaries are Cyprotex Discovery Limited and Cyprotex US, LLC (formerly Apredica LLC. Cyprotex provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical.

Directors: Anthony Baxter (CEO) 55, John Dootson (CFO) 53, Mark Warburton (SEC) , Ian Johnson (NEC) 60, Ralph Harris (NED) 72, Christopher Mills (NED) 63,

No. of Employees: 121 No. of Shareholders: n/a

Last Annual December 31st, 2015
Last Interim December 31st, 2015
Incorporated October 25, 2001
Public Since February 15, 2002
Shares in Issue 22,468,340
Free Float 13.0m (58.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

CRX Share Price Performance CRXQuote
0.0  0.0%
Traded 1:00am · Minimum 15 min delayed · NMS: 3.00k

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Should you buy CRX

Access CRX Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis